Alzheimer's disease biomarkers and their current use in clinical research and practice

TR Hunter, LE Santos, F Tovar-Moll… - Molecular Psychiatry, 2024 - nature.com
While blood-based tests are readily available for various conditions, including
cardiovascular diseases, type 2 diabetes, and common cancers, Alzheimer's disease (AD) …

Neurofilament light chains to assess sepsis-associated encephalopathy: Are we on the track toward clinical implementation?

B Bircak-Kuchtova, HY Chung, J Wickel, J Ehler… - Critical Care, 2023 - Springer
Sepsis is the most common cause of admission to intensive care units worldwide. Sepsis
patients frequently suffer from sepsis-associated encephalopathy (SAE) reflecting acute …

Association of chronic kidney disease with plasma NfL and other biomarkers of neurodegeneration: the H70 birth cohort study in Gothenburg

A Dittrich, NJ Ashton, H Zetterberg, K Blennow… - Neurology, 2023 - AAN Enterprises
Background and Objectives Studies associate chronic kidney disease (CKD) with
neurodegeneration. This study investigated the relationship between kidney function, blood …

A neuroimaging biomarker for Individual Brain-Related Abnormalities In Neurodegeneration (IBRAIN): a cross-sectional study

K Zhao, P Chen, A Alexander-Bloch, Y Wei… - …, 2023 - thelancet.com
Background Alzheimer's disease (AD) is a prevalent neurodegenerative disorder that poses
a worldwide public health challenge. A neuroimaging biomarker would significantly improve …

Vascular dementia subtypes, pathophysiology, genetics, neuroimaging, biomarkers, and treatment updates along with its association with Alzheimer's dementia and …

P Prajjwal, MDM Marsool, P Inban, B Sharma… - Disease-a-Month, 2023 - Elsevier
Dementia is a chronic progressive cognitive decline illness that results in functional
impairment. Vascular dementia (VaD), second only to Alzheimer's disease (AD), is one of …

Greater cognitive reserve is related to lower cortical excitability in healthy cognitive aging, but not in early clinical Alzheimer's disease

SS Buss, PJ Fried, J Macone, V Zeng… - Frontiers in Human …, 2023 - frontiersin.org
Objective To investigate the relationship between cortico-motor excitability and cognitive
reserve (CR) in cognitively unimpaired older adults (CU) and in older adults with mild …

Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank

X Wang, Z Shi, Y Qiu, D Sun, H Zhou - BMC medicine, 2024 - Springer
Background Peripheral glial fibrillary acidic protein (GFAP) and neurofilament light chain
(NfL) are sensitive markers of neuroinflammation and neuronal damage. Previous studies …

Associations of plasma NfL, GFAP, and t-tau with cerebral small vessel disease and incident dementia: longitudinal data of the AGES-Reykjavik Study

ACE van Gennip, CL Satizabal, RP Tracy… - Geroscience, 2024 - Springer
We investigated the associations of plasma neurofilament light (NfL), glial fibrillary acidic
protein (GFAP), and total tau (t-tau) with markers of cerebral small vessel disease (SVD) and …

Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and …

S Mazzeo, A Ingannato, G Giacomucci… - European Journal of …, 2024 - Wiley Online Library
Background and purpose We aimed to evaluate the accuracy of plasma neurofilament light
chain (NfL) in predicting Alzheimer's disease (AD) and the progression of cognitive decline …

Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia

L Le Scouarnec, V Bouteloup, PJ van der Veere… - Alzheimer's Research & …, 2024 - Springer
Background The accumulation of amyloid-β (Aβ) peptide in the brain is a hallmark of
Alzheimer's disease (AD), occurring years before symptom onset. Current methods for …